SCHEMBL17455983

SCHEMBL17455983

c1ccc(CN2CCC(Oc3ccccc3-c3ccncc3)CC2)nc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.50
▸ RAB9A P51151 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ SCN5A Q14524 2/20 0.48
▸ SCN9A Q15858 2/20 0.48
▸ SCN8A Q9UQD0 1/20 0.46
▸ LMNA P02545 3/20 0.46
▸ PKM P14618 1/20 0.46
▸ SLC5A7 Q9GZV3 1/20 0.46
▸ KCNH2 Q12809 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ DRD4 P21917 1/20 0.44
▸ SIGMAR1 Q99720 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17455954 0.88 ALDH1A1 (0.48) ALDH1A1RAB9AL3MBTL1SCN5ASCN9A
SCHEMBL17456056 0.84 SCN9A (0.49) ALDH1A1RAB9ASCN9ASCN8ASMN1; SMN2
SCHEMBL17455938 0.84 SMN1; SMN2 (0.57) SCN5ASCN9AKCNH2SMN1; SMN2SIGMAR1
SCHEMBL17455950 0.81 CHRM3 (0.49) ALDH1A1LMNAKDM4ESMN1; SMN2KMT2A
SCHEMBL17456016 0.80 HRH1 (0.43) LMNAKCNH2SMN1; SMN2SIGMAR1
SCHEMBL17455967 0.80 SCN9A (0.51) ALDH1A1SCN9ASCN8ALMNAKDM4E
SCHEMBL17455948 0.80 SCN9A (0.52) ALDH1A1L3MBTL1SCN9ALMNAKDM4E
SCHEMBL17456009 0.77 SCN9A (0.47) ALDH1A1RAB9ASCN5ASCN9ASCN8A
SCHEMBL17456058 0.77 SCN9A (0.49) SCN5ASCN9ASMN1; SMN2DRD4GAA
SCHEMBL17456031 0.77 SMN1; SMN2 (0.49) ALDH1A1LMNAKDM4ESMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 ALDH1A1 65/4885RAB9A 2187/4885L3MBTL1 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback